+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07019220

Phase 2 Study of Gemcitabine Chemoablation for Treating Low-Grade Bladder Cancer Single Arm, Open-Label Trial Evaluating Safety and Effectiveness

Led by Ekaterina Laukhtina · Updated on 2025-06-13

47

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of intravesical chemoablation with gemcitabine in patients who have low-grade bladder cancer confirmed by biopsy. This open-label Phase 2 clinical trial aims to assess the treatments effectiveness, safety, and tolerability in this patient group. The study focuses on patients with recurrent or primary Ta low-grade bladder cancer who meet specific tumor size and lesion number limits. Participants will receive six weekly instillations of gemcitabine directly into the bladder. This treatment approach is designed to treat the bladder cancer locally without surgery. The study includes a single treatment arm with no placebo or comparator group. The treatment period will be followed by monitoring to evaluate responses and side effects. Throughout the study, patients will undergo cystoscopy and bladder examinations, including photo documentation of tumors, to assess clinical and pathological responses at the end of treatment and during follow-up visits at 1 and 3 months post-treatment. Patient-reported outcomes on quality of life and symptoms will be collected weekly during treatment and at follow-up visits. Researchers will monitor participants for safety and treatment effects during these visits, with the total study duration spanning several months.

CONDITIONS

Brief Title

Chemoablation for Low-Grade Bladder Cancer

Research Team

E

Ekaterina Laukhtina Dr., Medical Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here